Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Tryptamine Therapeutics.
RELATED STOCKHEAD STORIES
Stockhead TV
Long Shortz with Tryptamine Therapeutics: Fantastic fibromyalgia results off the back of US psychedelic trial
Stockhead TV
Break it Down: Tryptamine Therapeutics reports positive results for Fibromyalgia patients
Health & Biotech
ASX Health Stocks: Psilocybin drug shows promise for fibromyalgia pain relief
News
Market Highlights: Wall Street surges as Big Tech blows through forecasts; and 5 ASX small caps to watch today
News
CLOSING BELL: Corruption? In Africa? Over mining licences? That can’t be right, surely…
News
CLOSING BELL: ‘How to falter at the last furlong and limp home like a beaten favourite’, by the ASX
News
ASX February Winners: Semiconductor stocks shine in tough month for investors
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: Forcing the product to pay to be the product is about as Meta as it gets
News
ASX Small Caps Lunch Wrap: Who wants to watch China pull a CEO out of its hat today?
News
Rise and Shine: everything you need to know before the ASX opens
News
Weekly Small Cap and IPO wrap: Large and small caps stumble this week, Omnia Metals due diligence pays off
News
CLOSING BELL: If everything could just stop blowing up for a while, that’d be great.
Health & Biotech
Planets align as Exopharm advances its technologies and experts report that exosomes may hold the key to mRNA therapeutics
Health & Biotech
Exopharm makes big LEAP moving to Phase 2 of collaborative agreement with AIRM
News
ASX Quarterlies: Nuheara rockets 33pc, Dicker continues to grow, while these biotechs are all cashed up
Experts
